The Smart Insufflator
Spatium Medical introduces the world’s first medical insufflator that ensures stable workspace at lowest insufflation and ventilation pressure with three patented technologies addressing three unmet needs.
Patient benefit at the core of your investment.
Human+ is an early-stage investment fund that accelerates the translation of innovative biomedical research into products and treatments.
The translational gap
The development of new biomedical products is stagnating due to the gap between scientific research and product development. While new scientific discoveries arise at an ever-increasing pace, translation of these research outcomes into new products and treatments for patients is lagging behind.
Bridging the gap
Human+ supports bridging this translational gap through improved project risk mitigation and shared funding risk.
Investment ProjectsHigh potential innovations
Precision surgery for cancer treatment
Bcon Medical designs electromagnetic navigation systems to improve cancer surgery.
Preventing death from colorectal cancer
CRCBioScreen has a single objective – preventing death from colorectal cancer. The company’s early diagnostic multiFIT combines three protein biomarkers to
increase the yield of CRC screening.
For whom
Together we can
Human+ provides an exquisite opportunity for scientists, funders and investors to jointly develop effective medical products and diagnostics for patients.
Scientists
Human+ offers a unique co-financing model to foster high potential research projects and bring the outcomes to patients.
Investors
Human+ combines Return on Impact and sound Return on Investment targets for its funders.
Human+ Fund
- Gustav Mahlerplein 105
- 1082 MS Amsterdam
- The Netherlands